Designing p53 trials: A surgical oncologists view

p53 in the Clinics

Volumn , Issue , 2014, Pages 289-303

  Kandioler, Daniela ^a   Kappel, Sonja ^a   Wolf, Brigitte ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930702263     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3676-8_16     Document Type: Chapter

References (56)

1. Bates S, Vousden KH (1999) Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37
2. Bedikian AY, Johnson MM, Warneke CL et al (2011) Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res 21:84-90
3. Bennett R, Schneider H, Estrella E et al (2009) Automated DNA mutation detection using universal conditions direct sequencing: application to ten muscular dystrophy genes. BMC Genet 10:66
4. Beroud C, Soussi T (2003) The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176-181
5. Bonnefoi H, Piccart M, Bogaerts J et al (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 12:527-539
6. Bossuyt PM, Reitsma JB, Brans DE et al (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7-18
7. Brown PD, Krishnan S, Sarkaria JN et al (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26:5603-5609
8. Chakravarty G, Redkar A, Mittra I (1996) A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer 74:1181-1187
9. Cuzick J, Fisher G, Kattan MW et al (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186-1194
10. de Graeff P, Hall J, Crijns AP et al (2006) Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 95:627-633
11. de Jong KP, Gouw AS, Peeters PM et al (2005) P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11:4067-4073
12. De Vries EM, Ricke DO, De Vries TN et al (1996) Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. Hum Mutat 7:202-213
13. Dookeran KA, Dignam JJ, Ferrer K et al (2010) p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 17:1398-1405
14. Goebell PJ, Groshen SG, Schmitz-Drager BJ (2010) p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 28:377-388
15. Graziano SL, Tatum A, Herndon JEII et al (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-123
16. Hainaut P, Soussi T, Shomer B et al (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25:151-157
17. Hall PA, McCluggage WG (2006) Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J Pathol 208:1-6
18. Hanazono K, Natsugoe S, Stein HJ et al (2006) Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. Oncol Rep 15:821-824
19. Henry NL, Hayes DF (2006) Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11:541-552
20. HoUstein M, Shomer B, Greenblatt M et al (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141-146
21. Hutchison CA (2007) DNA sequencing: bench to bedside and beyond. Nucleic Acids Res 35:6227-6237
22. Jung SY, Jeong J, Shin SH et al (2011) Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to st gallen consensus and intrinsic subtypes. J Surg Oncol 103:207-211
23. Kandioler D (2008) Personalized medicine-p53 gene analysis for prediction of response to neoadjuvant therapy in esophageal cancer. MEMO 1:137-142
24. Kandioler D, Zwrtek R, Ludwig C et al (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235:493-498
25. Kandioler D, Hejna M, Zwrtek R et al (2007) p53 Research Group Study. p53 adapted neoadjuvant therapy for esophageal cancer: pilot study. Annual Meeting 2007, American Society of Clinical Oncology, Abstract 4535
26. Kandioler D, Stamatis G, Eberhardt W et al (2008) Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 135:1036-1041
27. Kandioler-Eckersberger D, Kappel S, Mittlbock M et al (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117:744-750
28. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpres-sion for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56
29. Karim S, Ali A (2009) Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol 15:1381-1387
30. Kim T, Grobmyer SR, Smith R et al (2011) Esophageal cancer-the five year survivors. J Surg Oncol 103:179-183
31. Kinahan PE, Doot RK, Wanner-Roybal M et al (2009) PET/CT assessment of response to therapy: tumor change measurement, truth data, and error. Transl Oncol 2:223-230
32. Kudahetti S, Fisher G, Ambroisine L et al (2009) p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 104:20-24
33. Lan YT, Chang SC, Li AF et al (2007) p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 22:499-506
34. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749-758
35. Malats N, Bustos A, Nascimento CM et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678-686
36. Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034
37. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
38. Moher D, Schulz KF, Altman D (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991
39. Munro AJ, Lain S, Lane DP (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92:434-444
40. Nottage M, Siu LL (2002) Principles of clinical trial design. J Clin Oncol 20:42S-46S
41. Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008
42. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-629
43. Popat S, Chen Z, Zhao D et al (2006) A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 17:1810-1817
44. Robles Al, Harris CC (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2:a001016
45. Sanchez-Munoz A, Duenas-Garcia R, Jaen-Morago A et al (2010) Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine +/-trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 33:432-437
46. Sargent DJ, Conley BA, Allegra C et al (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027
47. Singer G, Stohr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218-224
48. Smith DR, Ji CY, Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216-223
49. Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene 26:2145-2156
50. Stewart DJ (2010) Randomized phase II trials: misleading and unreliable. J Clin Oncol 28:e649-650, author reply e651-653
51. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
52. Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039
53. Topova L, Hellmich G, Puffer E et al (2011) Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum 54:401-411
54. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol CeU Biol 8:275-283
55. Yamashita H, Nishio M, Toyama T et al (2004) Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24-R30
56. Yeo SG, Kim DY, Kim TH et al (2010) Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 252:998-1004